Uit het jaarverslag:
Our objectives for 2022 are to continue to pursue our three
pillar strategy; to grow our commercialization to fully capitalize
on the robust sales of RUCONEST® globally, also in preparation
for the launch of leniolisib, expected in early 2023. As we
approach the launch of leniolisib we will continue to make
significant investments in pre-launch activities will continue to
be made. The Company expects that this will have a negative
effect on the profit in the year 2022. Consequently, the
Company expects the cash and cash equivalents to reduce
during the year as the Company invests in its future. Expected
revenue for leniolisib, if approved, will increase significantly
from 2023 and onwards.
In addition, the Company will evaluate the lifecycle
management of both rhC1INH and PI3Kd in new indications.
As in 2021, the Company will continue to search for viable inlicensing or acquisition opportunities to bolster its pipeline both near- and long-term.
Lastly, as Pharming grows in size and maturity, the Company
believes it has a responsibility to its employees and its
stakeholders to report on its environmental, social and
governance (ESG) impact. As such, the Company will set up an
ESG committee with the goal of creating a proactive program
to establish ESG goals and a plan to continue building a